HomeTrialNCT05040373
🔬NCT05040373RECRUITING

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Study Summary

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment10 participants
Primary Completion
Lead SponsorAlnylam Pharmaceuticals
Data Retrieved2026-04-11 02:53:26.219305+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.